NasdaqCM - Delayed Quote USD
China SXT Pharmaceuticals, Inc. (SXTC)
At close: October 21 at 4:00 PM EDT
Pre-Market: 6:00 AM EDT
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
1,928.4970
1,928.4970
1,971.6790
2,602.2810
4,777.5730
--
Cost of Revenue
1,374.5260
1,374.5260
1,545.4080
1,350.6380
1,938.0230
--
Gross Profit
553.9710
553.9710
426.2710
1,251.6430
2,839.5500
--
Operating Expense
3,069.1880
3,069.1880
6,033.7800
6,441.3160
5,036.6260
--
Operating Income
-2,515.2170
-2,515.2170
-5,607.5090
-5,189.6730
-2,197.0760
--
Net Non Operating Interest Income Expense
-544.2790
-544.2790
-476.7760
-36.6950
-1,615.4400
--
Other Income Expense
-39.0360
-39.0360
149.5130
-181.5810
871.6500
--
Pretax Income
-3,098.5320
-3,098.5320
-5,934.7720
-5,407.9490
-2,940.8660
--
Tax Provision
--
--
--
328.1460
-192.6830
--
Net Income Common Stockholders
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
--
Diluted NI Available to Com Stockholders
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
--
Basic EPS
-26.95
-3.57
-22.23
-137.92
-95.47
--
Diluted EPS
-26.95
-3.57
-22.23
-137.92
-95.47
--
Basic Average Shares
466.5480
867.4220
266.9730
41.5910
28.7810
--
Diluted Average Shares
466.5480
867.4220
266.9730
41.5910
28.7810
--
Total Operating Income as Reported
-2,515.2170
-2,515.2170
-5,607.5090
-5,189.6730
-2,197.0760
--
Total Expenses
4,443.7140
4,443.7140
7,579.1880
7,791.9540
6,974.6490
--
Net Income from Continuing & Discontinued Operation
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
--
Normalized Income
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
--
Interest Expense
544.2790
544.2790
476.7760
36.6950
--
--
Net Interest Income
-544.2790
-544.2790
-476.7760
-36.6950
-1,615.4400
--
EBIT
-2,554.2530
-2,554.2530
-5,457.9960
-5,371.2540
-2,197.0760
--
EBITDA
-2,351.0060
-2,351.0060
-5,207.8340
-5,051.2470
-1,851.6620
--
Reconciled Cost of Revenue
1,374.5260
1,374.5260
1,545.4080
1,350.6380
1,938.0230
--
Reconciled Depreciation
203.2470
203.2470
250.1620
320.0070
345.4140
--
Net Income from Continuing Operation Net Minority Interest
-3,098.5320
-3,098.5320
-5,934.7720
-5,736.0950
-2,748.1830
--
Total Unusual Items Excluding Goodwill
--
--
--
--
--
-5,625.9160
Total Unusual Items
--
--
--
--
--
-5,625.9160
Normalized EBITDA
-2,351.0060
-2,351.0060
-5,207.8340
-5,051.2470
-1,851.6620
--
Tax Rate for Calcs
--
--
--
0.0003
0.0001
--
3/31/2020 - 1/4/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PRFX PainReform Ltd.
0.7401
+7.26%
UPC Universe Pharmaceuticals INC
0.4043
-3.05%
YCBD cbdMD, Inc.
0.5199
+1.94%
SNOA Sonoma Pharmaceuticals, Inc.
2.9700
-6.01%
AKAN Akanda Corp.
1.0700
-2.73%
PTPI Petros Pharmaceuticals, Inc.
0.4174
+30.44%
CPHI China Pharma Holdings, Inc.
0.2350
-5.62%
CTOR Citius Oncology, Inc.
1.1900
-3.25%
QNTM Quantum BioPharma Ltd.
6.81
-9.80%
SHPH Shuttle Pharmaceuticals Holdings, Inc.
1.2900
+8.40%